Prevention of relapse in patients w/ reflux esophagitis. Short-term symptomatic relief & healing of active duodenal & benign gastric ulcer, GERD & history of erosive esophagitis. In combination w/ clarithromycin & either amoxicillin or metronidazole for active duodenal ulcer in H. pylori +ve patients. Pathological hypersecretory conditions associated w/ Zollinger-Ellison syndrome in adults.
AdultGERD associated w/ history of erosive esophagitis 40 mg once daily by IV infusion for 7-10 days. Pathological hypersecretion including Zollinger-Ellison syndrome 80 mg IV every 12 hr. Renal impairment Max: 40 mg daily. Hepatic impairment Max: 20 mg daily or 40 mg on alternate days.
Anaphylaxis & other serious reactions eg, erythema multiforme, SJS & TEN. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Thrombophlebitis. Increased risk of C. difficile-associated diarrhea & osteoporosis-related fractures of the hip, wrist or spine. Mild, transient transaminase elevations & hypomagnesemia. May produce false +ve urine screen for tetrahydroxycannabinol. Concomitant use w/ MTX. Pregnancy & lactation. Childn. Elderly ≥65 yr.
A02BC02 - pantoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
